(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 July 2013 (18.07.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/106570 A1

(51) **International Patent Classification**:
A61K 31/197 (2006.01) *A61P 17/02* (2006.01)

(21) **International Application Number**:
PCT/US2013/021029

(22) **International Filing Date**:
10 January 2013 (10.01.2013)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/585,265 11 January 2012 (11.01.2012) US

(71) **Applicant**: **ABBOTT LABORATORIES** [US/US]; Dept. 377/AP6A-1, 100 Abbott Park Road, Abbott Park, Illinois 60064 (US).

(72) **Inventors**: **NELSON, Jeffrey L.**; 7152 Donnybrook Drive, Dublin, Ohio 43017 (US). **VOSS, Anne C.**; 1526 Bridgeton Drive, Columbus, Ohio 43220 (US). **BAGGS, Maria G.**; 6668 Belleshire Street, Columbus, Ohio 43229 (US). **PAULE, Charles L.**; 90 Juniper Avenue, Westerville, Ohio 43081 (US). **HEGAZI, Refaat A.**; 5909 Brigids Close Drive, Dublin, Ohio 43017 (US). **SUAREZ, Fabrizis**; 4871 Stone Place, New Albany, Ohio 43054 (US). **FANJIANG, Gary**; 208 Creekside Plaza, Gahanna, Ohio 43230 (US).

(74) **Agents**: **JOVANOVIC, Milan** et al.; Abbott Nutrition a Division of, Abbott Laboratories, 3300 Stelzer Road, Dept 108140 RP3-2, Columbus, Ohio 43219 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2013/106570 A1

(54) **Title**: COMBINATION OF BETA-HYDROXY-BETA-METHYLBUTYRATE, ARGININE AND GLUTAMINE FOR USE IN TREATING DIABETIC ULCERS

(57) **Abstract**: Disclosed is the combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine for use in a method of treating a diabetic ulcer in a diabetic individual having at least one of: (a) a serum albumin level of less than or equal to 4.0 g/dL, and/or (b) an Ankle-Brachial Index of less than 1.0. 9. Also disclosed is the use of the combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine for the manufacture of a medicament for use in the treatment of a diabetic ulcer in a diabetic individual having at least one of: (a) a serum albumin level of less than or equal to 4.0 g/dL, and/or (b) an Ankle-Brachial Index of less than 1.0. In certain embodiments, the combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine are orally administered via a nutritional composition.